LNTH
Lantheus Holdings, Inc.
Price Chart
Latest Quote
$107.10
+2.25 (+2.15%)
Current Price
| Previous Close | $104.85 |
| Open | $105.94 |
| Day High | $107.80 |
| Day Low | $105.61 |
| Volume | 42,625 |
Stock Information
| Shares Outstanding | 65.11M |
| Total Debt | $625.75M |
| Cash Equivalents | $498.58M |
| Revenue | $1.55B |
| Net Income | $279.03M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $6.97B |
| P/E Ratio | 25.56 |
| EPS (TTM) | $4.19 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.95B |
| Sales | $1.55B |
| Income | $279.03M |
| Book/sh | $18.63 |
| Cash/sh | $7.66 |
| Employees | 1K |
Financial Ratios
| Quick Ratio | 2.57 |
| Current Ratio | 2.83 |
| Debt/Eq | 51.62 |
| EPS Growth TTM | 62.30% |
Returns & Margins
| ROA | 8.15% |
| ROE | 23.48% |
| Gross Margin | 60.48% |
| Operating Margin | 21.65% |
| Profit Margin | 18.05% |
Ownership
| Insider Ownership | 2.09% |
| Institutional Ownership | 115.54% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 16.74 |
| P/S | 4.51 |
| P/B | 5.75 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $105.23 |
Technical Indicators
| SMA20 | $102.32 |
| SMA50 | $94.65 |
| SMA200 | $71.90 |
| RSI | 63.10 |
| ATR | 3.0639 |
| Shares Float | 58.36M |
| Short Float | 11.20% |
| Short Ratio | 4.75 |
| Volatility | -0.04 |
| Rel Volume | 0.05 |
Performance History
| Week | +3.79% |
| Month | +7.04% |
| Quarter | +41.61% |
| 6 Months | +57.48% |
| YTD | +59.21% |
| Year | +32.30% |
| 3 Years | +15.32% |
| 5 Years | +331.51% |
| 10 Years | +3300.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $107.10 | 42,625 |
| 2026-06-24 | $104.85 | 829,500 |
| 2026-06-23 | $106.03 | 757,500 |
| 2026-06-22 | $106.20 | 630,200 |
| 2026-06-18 | $103.86 | 1,090,900 |
| 2026-06-17 | $103.19 | 933,400 |
| 2026-06-16 | $105.03 | 1,423,700 |
| 2026-06-15 | $104.67 | 798,600 |
| 2026-06-12 | $104.52 | 687,500 |
| 2026-06-11 | $104.32 | 1,226,300 |
| 2026-06-10 | $100.24 | 651,900 |
| 2026-06-09 | $99.98 | 659,400 |
| 2026-06-08 | $100.01 | 751,500 |
| 2026-06-05 | $100.98 | 746,200 |
| 2026-06-04 | $102.82 | 826,200 |
| 2026-06-03 | $100.25 | 1,082,200 |
| 2026-06-02 | $96.30 | 1,029,800 |
| 2026-06-01 | $97.13 | 839,600 |
| 2026-05-29 | $99.30 | 1,376,600 |
| 2026-05-28 | $99.62 | 884,300 |
| 2026-05-27 | $99.09 | 1,607,800 |
| 2026-05-26 | $100.06 | 1,566,800 |
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
đ° Latest News
Healthcare Equipment and Supplies Stocks Q1 Teardown: Lantheus (NASDAQ:LNTH) Vs The Rest
StockStory âĸ 2026-06-24T13:52:25Z
3 Healthcare Stocks with Open Questions
StockStory âĸ 2026-06-12T09:58:56Z
1 Cash-Producing Stock on Our Buy List and 2 Facing Challenges
StockStory âĸ 2026-06-08T10:53:50Z
Assessing Lantheus Holdings (LNTH) Valuation After Strong Multi Month Share Price Gains
Simply Wall St. âĸ 2026-06-05T12:08:07Z
Why This Fund Cashed Out of a Stock That Soared 250% in Just One Year
Motley Fool âĸ 2026-05-31T21:54:17Z
Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports
Reuters âĸ 2026-05-22T20:36:53Z
How The Story On Lantheus Holdings (LNTH) Is Shifting With PYLARIFY And Pipeline Expectations
Simply Wall St. âĸ 2026-05-22T17:09:31Z
3 Hyped Up Stocks with Warning Signs
StockStory âĸ 2026-05-18T09:24:55Z
Big Pharmaâs 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
24/7 Wall St. âĸ 2026-05-14T13:20:55Z
We Think You Should Be Aware Of Some Concerning Factors In Lantheus Holdings' (NASDAQ:LNTH) Earnings
Simply Wall St. âĸ 2026-05-14T11:14:32Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $599,657,000 | $545,619,000 | $586,886,000 | $353,358,000 |
| Cost Of Revenue | $599,657,000 | $545,619,000 | $586,886,000 | $353,358,000 |
| Total Revenue | $1,541,609,000 | $1,533,910,000 | $1,296,429,000 | $935,061,000 |
| Operating Revenue | $1,541,609,000 | $1,533,910,000 | $1,296,429,000 | $935,061,000 |
| Expenses | ||||
| Interest Expense | $19,749,000 | $19,669,000 | $20,019,000 | $7,185,000 |
| Total Expenses | $1,226,050,000 | $1,085,346,000 | $931,787,000 | $898,866,000 |
| Other Income Expense | $-5,409,000 | $-34,756,000 | $46,682,000 | $-4,904,000 |
| Other Non Operating Income Expenses | $-52,000 | $1,020,000 | $-143,000 | - |
| Net Non Operating Interest Income Expense | $3,642,000 | $17,169,000 | $-381,000 | $-4,572,000 |
| Interest Expense Non Operating | $19,749,000 | $19,669,000 | $20,019,000 | $7,185,000 |
| Operating Expense | $626,393,000 | $539,727,000 | $344,901,000 | $545,508,000 |
| Other Operating Expenses | $-4,727,000 | - | - | - |
| Selling And Marketing Expense | $178,691,000 | $177,940,000 | $141,736,000 | $100,243,000 |
| General And Administrative Expense | $275,121,000 | $193,689,000 | $125,458,000 | $133,584,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $233,559,000 | $312,442,000 | $326,661,000 | $28,067,000 |
| Net Interest Income | $3,642,000 | $17,169,000 | $-381,000 | $-4,572,000 |
| Interest Income | $23,391,000 | $36,838,000 | $19,638,000 | $2,613,000 |
| Normalized Income | $237,544,608 | $338,379,600 | $289,435,125 | $31,941,160 |
| Net Income From Continuing And Discontinued Operation | $233,559,000 | $312,442,000 | $326,661,000 | $28,067,000 |
| Total Operating Income As Reported | $310,832,000 | $456,979,000 | $364,642,000 | $36,195,000 |
| Net Income Common Stockholders | $233,559,000 | $312,442,000 | $326,661,000 | $28,067,000 |
| Net Income | $233,559,000 | $312,442,000 | $326,661,000 | $28,067,000 |
| Net Income Including Noncontrolling Interests | $233,559,000 | $312,442,000 | $326,661,000 | $28,067,000 |
| Net Income Continuous Operations | $233,559,000 | $312,442,000 | $326,661,000 | $28,067,000 |
| Pretax Income | $313,792,000 | $430,977,000 | $410,943,000 | $26,719,000 |
| Special Income Charges | $4,266,000 | $8,521,000 | $46,846,000 | $-4,648,000 |
| Interest Income Non Operating | $23,391,000 | $36,838,000 | $19,638,000 | $2,613,000 |
| Operating Income | $315,559,000 | $448,564,000 | $364,642,000 | $36,195,000 |
| Gross Profit | $941,952,000 | $988,291,000 | $709,543,000 | $581,703,000 |
| Per Share | ||||
| Diluted EPS | $3.41 | $4.36 | $4.65 | $0.40 |
| Basic EPS | $3.46 | $4.52 | $4.79 | $0.41 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,371,392 | $-9,838,400 | $9,599,125 | $-1,029,840 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $408,996,000 | $551,046,000 | $444,180,000 | $86,737,000 |
| Total Unusual Items | $-5,357,000 | $-35,776,000 | $46,825,000 | $-4,904,000 |
| Total Unusual Items Excluding Goodwill | $-5,357,000 | $-35,776,000 | $46,825,000 | $-4,904,000 |
| Reconciled Depreciation | $70,098,000 | $64,624,000 | $60,043,000 | $47,929,000 |
| EBITDA (Bullshit earnings) | $403,639,000 | $515,270,000 | $491,005,000 | $81,833,000 |
| EBIT | $333,541,000 | $450,646,000 | $430,962,000 | $33,904,000 |
| Diluted Average Shares | $68,443,000 | $71,651,000 | $70,239,000 | $70,671,000 |
| Basic Average Shares | $67,489,000 | $69,199,000 | $68,266,000 | $68,487,000 |
| Diluted NI Availto Com Stockholders | $233,559,000 | $312,442,000 | $326,661,000 | $28,067,000 |
| Tax Provision | $80,233,000 | $118,535,000 | $84,282,000 | $-1,348,000 |
| Gain On Sale Of Ppe | $5,000,000 | $8,415,000 | $51,789,000 | $0 |
| Other Special Charges | $734,000 | $-106,000 | $4,943,000 | $4,648,000 |
| Gain On Sale Of Security | $-9,623,000 | $-44,297,000 | $-21,000 | $-256,000 |
| Research And Development | $177,308,000 | $168,098,000 | $77,707,000 | $311,681,000 |
| Selling General And Administration | $453,812,000 | $371,629,000 | $267,194,000 | $233,827,000 |
| Other Gand A | $275,121,000 | $193,689,000 | $125,458,000 | $133,584,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $127,501,000 | $865,061,000 | $602,718,000 | $70,673,000 |
| Total Assets | $2,227,399,000 | $1,980,340,000 | $1,651,149,000 | $1,321,258,000 |
| Total Non Current Assets | $1,327,435,000 | $653,707,000 | $565,330,000 | $643,642,000 |
| Other Non Current Assets | $19,069,000 | $8,154,000 | $9,936,000 | $15,322,000 |
| Non Current Deferred Assets | $109,196,000 | $170,233,000 | $150,198,000 | $110,647,000 |
| Non Current Deferred Taxes Assets | $109,196,000 | $170,233,000 | $150,198,000 | $110,647,000 |
| Investmentin Financial Assets | $42,213,000 | $39,489,000 | $0 | - |
| Goodwill And Other Intangible Assets | $962,296,000 | $222,950,000 | $213,174,000 | $376,474,000 |
| Other Intangible Assets | $722,779,000 | $161,761,000 | $151,985,000 | $315,285,000 |
| Current Assets | $899,964,000 | $1,326,633,000 | $1,085,819,000 | $677,616,000 |
| Other Current Assets | $650,000 | $953,000 | $246,000 | $205,000 |
| Assets Held For Sale Current | $80,742,000 | $0 | $7,159,000 | $0 |
| Prepaid Assets | $20,750,000 | $15,406,000 | $16,437,000 | $12,887,000 |
| Inventory | $64,674,000 | $68,025,000 | $64,029,000 | $35,475,000 |
| Receivables | $374,027,000 | $329,435,000 | $284,292,000 | $213,397,000 |
| Taxes Receivable | $15,387,000 | $8,177,000 | - | - |
| Accounts Receivable | $358,640,000 | $321,258,000 | $284,292,000 | $213,397,000 |
| Allowance For Doubtful Accounts Receivable | $-9,500,000 | $-7,800,000 | - | - |
| Gross Accounts Receivable | $368,140,000 | $329,058,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $359,121,000 | $912,814,000 | $713,656,000 | $415,652,000 |
| Cash And Cash Equivalents | $359,121,000 | $912,814,000 | $713,656,000 | $415,652,000 |
| Debt | ||||
| Net Debt | $210,295,000 | - | - | $142,414,000 |
| Total Debt | $619,432,000 | $619,438,000 | $616,946,000 | $583,508,000 |
| Long Term Debt And Capital Lease Obligation | $618,694,000 | $618,464,000 | $616,123,000 | $583,154,000 |
| Long Term Debt | $568,678,000 | $565,279,000 | $561,670,000 | $557,712,000 |
| Current Debt And Capital Lease Obligation | $738,000 | $974,000 | $823,000 | $354,000 |
| Current Debt | $738,000 | $974,000 | $823,000 | $354,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,137,602,000 | $892,329,000 | $835,257,000 | $874,111,000 |
| Total Non Current Liabilities Net Minority Interest | $804,183,000 | $651,803,000 | $647,907,000 | $626,410,000 |
| Other Non Current Liabilities | $131,105,000 | $9,995,000 | $8,868,000 | $20,713,000 |
| Non Current Deferred Liabilities | $54,246,000 | $0 | - | - |
| Non Current Deferred Taxes Liabilities | $54,246,000 | $0 | - | - |
| Current Liabilities | $333,419,000 | $240,526,000 | $187,350,000 | $247,701,000 |
| Other Current Liabilities | $41,039,000 | $10,397,000 | $11,906,000 | $125,225,000 |
| Payables And Accrued Expenses | $228,398,000 | $180,892,000 | $138,290,000 | $91,697,000 |
| Payables | $46,480,000 | $36,151,000 | $41,189,000 | $20,563,000 |
| Total Tax Payable | $3,574,000 | $1,591,000 | - | - |
| Income Tax Payable | $3,574,000 | $1,591,000 | - | - |
| Accounts Payable | $42,906,000 | $34,560,000 | $41,189,000 | $20,563,000 |
| Equity | ||||
| Common Stock Equity | $1,089,797,000 | $1,088,011,000 | $815,892,000 | $447,147,000 |
| Total Equity Gross Minority Interest | $1,089,797,000 | $1,088,011,000 | $815,892,000 | $447,147,000 |
| Stockholders Equity | $1,089,797,000 | $1,088,011,000 | $815,892,000 | $447,147,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,307,000 | $-1,615,000 | $-1,037,000 | $-1,259,000 |
| Other Equity Adjustments | $-1,307,000 | $-1,615,000 | $-1,037,000 | $-1,259,000 |
| Retained Earnings | $679,504,000 | $445,945,000 | $133,503,000 | $-193,158,000 |
| Other | ||||
| Treasury Shares Number | $7,241,000 | $2,455,000 | $1,339,000 | $1,339,000 |
| Ordinary Shares Number | $64,586,000 | $68,450,000 | $68,524,000 | $67,512,000 |
| Share Issued | $71,827,000 | $70,905,000 | $69,863,000 | $68,851,000 |
| Tangible Book Value | $127,501,000 | $865,061,000 | $602,718,000 | $70,673,000 |
| Invested Capital | $1,659,213,000 | $1,654,264,000 | $1,378,385,000 | $1,005,213,000 |
| Working Capital | $566,545,000 | $1,086,107,000 | $898,469,000 | $429,915,000 |
| Capital Lease Obligations | $50,016,000 | $53,185,000 | $54,453,000 | $25,442,000 |
| Total Capitalization | $1,658,475,000 | $1,653,290,000 | $1,377,562,000 | $1,004,859,000 |
| Treasury Stock | $477,438,000 | $175,000,000 | $75,000,000 | $75,000,000 |
| Additional Paid In Capital | $888,320,000 | $817,972,000 | $757,727,000 | $715,875,000 |
| Capital Stock | $718,000 | $709,000 | $699,000 | $689,000 |
| Common Stock | $718,000 | $709,000 | $699,000 | $689,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $50,016,000 | $53,185,000 | $54,453,000 | $25,442,000 |
| Long Term Provisions | $138,000 | $23,344,000 | $22,916,000 | $22,543,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $63,244,000 | $48,263,000 | $36,331,000 | $30,425,000 |
| Current Accrued Expenses | $181,918,000 | $144,741,000 | $97,101,000 | $71,134,000 |
| Investments And Advances | $42,213,000 | $39,489,000 | $0 | - |
| Available For Sale Securities | $42,213,000 | $39,489,000 | - | - |
| Goodwill | $239,517,000 | $61,189,000 | $61,189,000 | $61,189,000 |
| Net PPE | $194,661,000 | $212,881,000 | $192,022,000 | $141,199,000 |
| Accumulated Depreciation | $-72,790,000 | $-108,762,000 | $-107,023,000 | $-100,128,000 |
| Gross PPE | $267,451,000 | $321,643,000 | $299,045,000 | $241,327,000 |
| Construction In Progress | $17,406,000 | $27,498,000 | $40,964,000 | $14,047,000 |
| Other Properties | $30,975,000 | $36,083,000 | $45,325,000 | $19,033,000 |
| Machinery Furniture Equipment | $166,137,000 | $163,059,000 | $129,835,000 | $118,468,000 |
| Buildings And Improvements | $49,913,000 | $85,523,000 | $73,441,000 | $76,329,000 |
| Land And Improvements | $3,020,000 | $9,480,000 | $9,480,000 | $13,450,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $22,412,000 | $23,075,000 | $18,963,000 | $7,254,000 |
| Work In Process | $16,335,000 | $15,870,000 | $13,807,000 | $8,234,000 |
| Raw Materials | $25,927,000 | $29,080,000 | $31,259,000 | $19,987,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $348,639,000 | $465,125,000 | $258,705,000 | $263,434,000 |
| Operating Activities | ||||
| Operating Cash Flow | $390,141,000 | $544,750,000 | $305,260,000 | $281,781,000 |
| Cash Flow From Continuing Operating Activities | $390,141,000 | $544,750,000 | $305,260,000 | $281,781,000 |
| Operating Gains Losses | $-5,000,000 | $-8,415,000 | $-51,789,000 | $-4,906,000 |
| Investing Activities | ||||
| Capital Expenditure | $-41,502,000 | $-79,625,000 | $-46,555,000 | $-18,347,000 |
| Investing Cash Flow | $-627,168,000 | $-226,015,000 | $5,939,000 | $-276,547,000 |
| Cash Flow From Continuing Investing Activities | $-627,168,000 | $-226,015,000 | $5,939,000 | $-276,547,000 |
| Capital Expenditure Reported | $-36,089,000 | $-51,625,000 | $-46,555,000 | $-18,347,000 |
| Net Other Investing Changes | - | $-63,144,000 | $52,494,000 | $-258,200,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-300,017,000 | $-100,000,000 | $0 | $-75,000,000 |
| Issuance Of Capital Stock | $3,727,000 | $3,450,000 | $1,933,000 | $1,375,000 |
| Financing Cash Flow | $-316,584,000 | $-118,536,000 | $-13,062,000 | $311,691,000 |
| Cash Flow From Continuing Financing Activities | $-316,584,000 | $-118,536,000 | $-13,062,000 | $311,691,000 |
| Net Other Financing Charges | $-26,338,000 | $-24,946,000 | $-18,094,000 | $-4,586,000 |
| Net Common Stock Issuance | $-296,290,000 | $-96,550,000 | $1,933,000 | $-73,625,000 |
| Common Stock Issuance | $3,727,000 | $3,450,000 | $1,933,000 | $1,375,000 |
| Other | ||||
| Repayment Of Debt | $-1,110,000 | $-318,000 | $-717,000 | $-175,385,000 |
| Interest Paid Supplemental Data | $15,094,000 | $15,094,000 | $15,387,000 | $5,064,000 |
| Income Tax Paid Supplemental Data | $69,037,000 | $153,815,000 | $151,579,000 | $54,049,000 |
| End Cash Position | $360,826,000 | $914,486,000 | $715,285,000 | $417,241,000 |
| Beginning Cash Position | $914,486,000 | $715,285,000 | $417,241,000 | $100,651,000 |
| Effect Of Exchange Rate Changes | $-49,000 | $-998,000 | $-93,000 | $-335,000 |
| Changes In Cash | $-553,611,000 | $200,199,000 | $298,137,000 | $316,925,000 |
| Proceeds From Stock Option Exercised | $7,154,000 | $3,278,000 | $3,816,000 | $7,537,000 |
| Common Stock Payments | $-300,017,000 | $-100,000,000 | $0 | $-75,000,000 |
| Net Issuance Payments Of Debt | $-1,110,000 | $-318,000 | $-717,000 | $382,365,000 |
| Net Long Term Debt Issuance | $-1,110,000 | $-318,000 | $-717,000 | $382,365,000 |
| Long Term Debt Payments | $-1,110,000 | $-318,000 | $-717,000 | $-175,385,000 |
| Net Business Purchase And Sale | $-585,666,000 | $-83,246,000 | $0 | $0 |
| Purchase Of Business | $-585,666,000 | $-83,246,000 | $0 | $0 |
| Net Intangibles Purchase And Sale | $-5,413,000 | $-28,000,000 | $0 | $0 |
| Purchase Of Intangibles | $-5,413,000 | $-28,000,000 | $0 | $0 |
| Change In Working Capital | $-44,234,000 | $2,048,000 | $-171,200,000 | $-75,065,000 |
| Change In Other Current Assets | $-5,406,000 | $4,440,000 | $-2,418,000 | $-2,973,000 |
| Change In Payables And Accrued Expense | $-11,574,000 | $37,963,000 | $-63,925,000 | $63,876,000 |
| Change In Accrued Expense | $-9,082,000 | $46,767,000 | $-81,114,000 | $63,575,000 |
| Change In Payable | $-2,492,000 | $-8,804,000 | $17,189,000 | $301,000 |
| Change In Account Payable | $-2,492,000 | $-8,804,000 | $17,189,000 | $301,000 |
| Change In Inventory | $-9,366,000 | $-2,670,000 | $-36,220,000 | $-7,508,000 |
| Change In Receivables | $-17,888,000 | $-37,685,000 | $-68,637,000 | $-128,460,000 |
| Changes In Account Receivables | $-17,888,000 | $-37,685,000 | $-68,637,000 | $-128,460,000 |
| Other Non Cash Items | $22,222,000 | $79,791,000 | $-120,000 | $300,288,000 |
| Stock Based Compensation | $85,563,000 | $76,393,000 | $50,507,000 | $29,262,000 |
| Unrealized Gain Loss On Investment Securities | $8,617,000 | $43,564,000 | $0 | $0 |
| Provisionand Write Offof Assets | $2,202,000 | $-904,000 | $7,914,000 | $7,145,000 |
| Asset Impairment Charge | $-4,727,000 | $0 | $138,050,000 | $0 |
| Deferred Tax | $21,841,000 | $-24,793,000 | $-54,806,000 | $-50,939,000 |
| Deferred Income Tax | $21,841,000 | $-24,793,000 | $-54,806,000 | $-50,939,000 |
| Depreciation Amortization Depletion | $70,098,000 | $64,624,000 | $60,043,000 | $47,929,000 |
| Depreciation And Amortization | $70,098,000 | $64,624,000 | $60,043,000 | $47,929,000 |
| Depreciation | $70,098,000 | $64,624,000 | $60,043,000 | $47,929,000 |
| Gain Loss On Sale Of PPE | $-5,000,000 | $0 | $-51,789,000 | $0 |
| Net Income From Continuing Operations | $233,559,000 | $312,442,000 | $326,661,000 | $28,067,000 |
| Issuance Of Debt | - | $0 | $0 | $557,750,000 |
| Long Term Debt Issuance | - | $0 | $0 | $557,750,000 |
| Gain Loss On Investment Securities | - | - | - | $-5,494,000 |
| Sale Of Business | - | - | - | - |
Fetched: 2026-06-20